Second MEVION S250i to Expand Proton Therapy Capacity in the Mountain West

Huntsman Cancer Institute adds a second compact proton therapy system, strengthening its leadership in the region

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems today announced that Huntsman Cancer Institute at the University of Utah has signed a contract for a second MEVION S250i Proton Therapy System.

Huntsman is the first and only proton therapy center in the Mountain West and has become a vital resource for patients across Utah, Idaho, Montana, Nevada, and Wyoming. Since opening the Senator Orrin G. Hatch Center for Proton Therapy in 2021, the institute has provided life-changing treatments for both adult and pediatric patients — with nearly one-third of its proton patients being children.

The new system will double treatment capacity and broaden access to patients with a wide range of cancers, including pediatric, head and neck, and breast cancers. Huntsman’s expansion ensures patients can receive advanced care close to home, rather than traveling to distant proton centers in Phoenix, Seattle, or San Diego.

The second system will be the latest-generation MEVION S250i, equipped with HYPERSCAN Pencil Beam Scanning and Adaptive Aperture pMLC, ensuring clinical and operational parity across both rooms. The existing system will also be upgraded to current specifications, so both rooms share the same advanced capabilities.

Tina Yu, Ph.D., CEO of Mevion Medical Systems, commented: “More and more cancer centers are adopting our 1+1 model — starting with a single system and expanding to two fully capable rooms. This is the most pragmatic and cost-effective approach to proton therapy. The benefits are clear: more patients treated with better economics, 100% uptime, expanded research opportunities, staged upgrades, and the ability to remain at the latest technology level without ever shutting down the center. Huntsman’s decision reinforces this model as the path forward for sustainable proton therapy growth.”

This second system demonstrates how the MEVION S250i platform enables strategic growth, allowing leading cancer centers to expand seamlessly by building on existing infrastructure and resources. It reflects a model of sustainable capacity expansion that creates a scalable pathway for bringing advanced care closer to patients.

About Mevion Medical Systems:
Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i and MEVION S250-FIT* with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

*The MEVION S250-FIT Proton Therapy System is not yet available for clinical use.